Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis

Published:2017-06-16 Issue:4 Volume:8 Page:705-726
ISSN:1869-6953
Container-title:Diabetes Therapy
language:en
Short-container-title:Diabetes Ther

Author:

Filipova Elena,Uzunova Katya,Kalinov Krassimir,Vekov Toni

Funder

Tchaikapharma High Quality Medicines Inc.

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://link.springer.com/content/pdf/10.1007/s13300-017-0273-4.pdf

Reference56 articles.

1. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953–6.

2. Ferwana M, Firwana B, Hasan R, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med. 2013;30(9):1026–32.

3. Charbonnel B, Roden M, Urquhart R, et al. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens. Diabetologia. 2005;48:553–60.

4. Staels B. Metformin and pioglitazone: effectively treating insulin resistance. Curr Med Res Opin. 2006;22:S27–37.

5. Chilcott J, Tappenden P, Jones ML, Wight JP. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther. 2001;23:1792–823 (discussion 1791).

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structure-based screening, optimization and biological evaluation of novel chrysin-based derivatives as selective PPARγ modulators for the treatment of T2DM and hepatic steatosis;European Journal of Medicinal Chemistry;2024-10

2. Raloxifene-driven benzothiophene derivatives: Discovery, structural refinement, and biological evaluation as potent PPARγ modulators based on drug repurposing;European Journal of Medicinal Chemistry;2024-04

3. An update review of post‐transplant diabetes mellitus: Concept, risk factors, clinical implications and management;Diabetes, Obesity and Metabolism;2024-04

4. MASLD treatment—a shift in the paradigm is imminent;Frontiers in Medicine;2023-12-11

5. Treating NASH by targeting peroxisome proliferator-activated receptors;Journal of Hepatology;2023-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3